Simulations Plus

Simulations Plus EBIT Margin

The EBIT Margin (Operating Margin) of Simulations Plus (SLP) as of Sep 27, 2026 is -89.33 %. In the previous year, EBIT Margin (Operating Margin) was 8.76 % — a change of -1,120.08% (lower).

EBIT Margin

-89.33 %

YoY

-1,120.08%

Last updated:

EBIT Margin (Operating Margin) of Simulations Plus is 2026 -89.33 % . EBIT Margin (Operating Margin) of Simulations Plus was 2025 8.76 % . It decreases by -1,120.08% lower compared to the previous year.

For Simulations Plus, the operating (EBIT) margin of -89.3% is down versus 24.2% a few years ago.

The Simulations Plus EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2018
34.71 USD
Jan 1, 2019
31.35 USD
Jan 1, 2020
27.90 USD
Jan 1, 2021
24.22 USD
Jan 1, 2022
27.66 USD
Jan 1, 2023
14.64 USD
Jan 1, 2024
8.76 USD
Jan 1, 2025
-89.33 USD
The Simulations Plus EBIT Margin history
YEAREBIT MarginYoY
-89.33 %-1,120.08%
8.76 %-40.20%
14.64 %-47.06%
27.66 %+14.22%
24.22 %-13.21%
27.90 %-10.98%
31.35 %-9.70%
34.71 %+1.38%
34.24 %-5.45%
36.21 %+13.23%
31.98 %-17.44%
38.74 %+9,478.97%
0.40 %+5.78%
0.38 %-5.38%
0.40 %+50.75%
0.27 %+35.24%
0.20 %-18.41%
0.24 %-14.04%
0.28 %+98.58%
0.14 %—
Access this data via the Eulerpool API
Get Free API Key

Simulations Plus Stock analysis

What does Simulations Plus do? Simulations Plus Inc is a company that offers software and services for the pharmaceutical industry. The company was founded in 1996 by Dr. Walt Woltosz and is headquartered in Lancaster, California. Simulations Plus began with the development of GastroPlus, a software that simulates the effects of drugs in the body using mathematical models. This software quickly became an important tool for the pharmaceutical industry to improve the effectiveness and safety of medications. Simulations Plus's business model is based on providing high-quality software and services for the pharmaceutical industry. They offer a wide range of products aimed at improving the effectiveness and safety of drugs by optimizing drug development and design. These products include software for simulating and analyzing the pharmacokinetics and dynamics of medications, a model for detecting and avoiding potential life-threatening liver damage, a cloud-based platform for simplifying the work of scientists and researchers, and services to assist with regulatory affairs and obtaining product approvals. Simulations Plus is known for its high-quality products and excellent customer support, and their various divisions and products contribute to improving the effectiveness and safety of medications, ultimately promoting patient health. The translation of the text is: "Simulations Plus Inc is a company that offers software and services for the pharmaceutical industry. The company was founded in 1996 by Dr. Walt Woltosz and is headquartered in Lancaster, California. Simulations Plus began with the development of GastroPlus, a software that simulates the effects of drugs in the body using mathematical models. This software quickly became an important tool for the pharmaceutical industry to improve the effectiveness and safety of medications. Simulations Plus's business model is based on providing high-quality software and services for the pharmaceutical industry. They offer a wide range of products aimed at improving the effectiveness and safety of drugs by optimizing drug development and design. These products include software for simulating and analyzing the pharmacokinetics and dynamics of medications, a model for detecting and avoiding potential life-threatening liver damage, a cloud-based platform for simplifying the work of scientists and researchers, and services to assist with regulatory affairs and obtaining product approvals. Simulations Plus is known for its high-quality products and excellent customer support, and their various divisions and products contribute to improving the effectiveness and safety of medications, ultimately promoting patient health." Simulations Plus is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Simulations Plus stock

EBIT Margin (Operating Margin) of Simulations Plus is -89.33 % in 2026.

EBIT Margin (Operating Margin) of Simulations Plus changed from 8.76 % to -89.33 %, representing a -1,120.08% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Simulations Plus since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Simulations Plus with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API
Get Free API Key

Margins — Simulations Plus

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Simulations Plus